Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Teva Pharmaceuticals
Biotech
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
Teva predicted ecopipam could become a preferred later-line therapy because it balances safety and efficacy better than existing drugs.
Nick Paul Taylor
Apr 29, 2026 9:07am
Teva's $400M Blackstone deal to fund Sanofi-partnered IBD drug
Mar 4, 2026 3:07am
Sanofi points to long-term efficacy of Teva-partnered IBD drug
Feb 17, 2026 8:05am
Fierce Pharma
Teva debuts innovation platform to parry key industry challenges
Nov 19, 2025 8:38am
Atai, Eli Lilly, Novartis & more—Chutes & Ladders
May 17, 2024 8:30am
New CEO will lead Teva at top of new year—Chutes & Ladders
Dec 2, 2022 9:30am
